PAOG Initiates Second CBD Nutraceutical Production Run As Early Results Of First Run Indicate Sell Out

SANDUSKY, OH, Nov. 2, 2021 /PRNewswire/ — PAO Group, Inc. (USOTC: PAOG) today announced initiating a second production run of the first CBD nutraceuticals products the company recently introduced.

PAOG recently announced the launch of its first two CBD nutraceutical products, RelaxRX CBD, a sleep aid, and RehabRX CBD, a salve.

PAOG has confirmed shipping its first and second CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (USOTC: USMJ).  Even before the product has been set up for sale online at www.USMJ.com, inquires for the product have indicated a rapid sellout.

Last year, the company acquired intellectual property form Nouveau Life Pharmaceuticals (NOUV) derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960).  PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property.

PAOG is on track to realize its first revenue this year, starting in Q4 2021, since acquiring the extraction technology.

PAOG has confirmed shipping its first and second CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (USOTC: USMJ).  The product will soon be for sale online at www.USMJ.com

PAOG expects revenue to grow rapidly following its first and second CBD nutraceutical product launches as the company has follow on products lined up to follow these products adding to overall sales potential.

Learn more about USMJ’s ecommerce site at www.usmj.com.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
(888) 979-2675
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/paog-initiates-second-cbd-nutraceutical-production-run-as-early-results-of-first-run-indicate-sell-out-301414412.html

SOURCE PAO Group, Inc.

PAOG Initiates Second CBD Nutraceutical Production Run As Early Results Of First Run Indicate Sell Out WeeklyReviewer

PR Newswire Business News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

Avatar of World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer